28 completed, 5 active not recruiting, 4 terminated, 3 withdrawn. 45 Phase 2, 8 Phase 3, 6 Phase 1.
Follow Angioedema: new trials by email Literature Review of Angioedema trials Research Report on Angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL) Berinert, Placebo for Berinert - Kidney Transplant | Phase 2 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 180 | 2025-09-22 | 2026-02-27 |
| Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients Deucrictibant XR tablet, Placebo comparator to XR tablet, Deucrictibant 20 mg capsule - Hereditary Angioedema (HAE), Angioedema | Phase 1 / Phase 2 | Recruiting | Institute for Asthma and Allergy | 10 | 2025-03-10 | 2025-07-02 |
| A Phase 2 in Adult Subjects With Hereditary Angioedema BW-20805 - Hereditary Angioedema (HAE) | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 25 | 2025-02-28 | 2026-04-17 |
| A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema STAR-0215 - Hereditary Angioedema | Phase 2 | Active not recruiting | Astria Therapeutics, Inc. | 56 | 2023-09-26 | 2025-07-23 |
| Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Povorcitinib, Placebo - Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Completed | Incyte Corporation | 136 | 2023-07-31 | 2026-03-12 |
| A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema Navenibart - Hereditary Angioedema | Phase 1 / Phase 2 | Completed | Astria Therapeutics, Inc. | 29 | 2023-02-21 | 2026-05-08 |
| Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema deucrictibant - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 / Phase 3 | Enrolling by invitation | Pharvaris Netherlands B.V. | 150 | 2022-12-28 | 2026-07-21 |
| Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients ADX-324, Placebo - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 53 | 2022-12-14 | 2026-06-16 |
| Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II Deucrictibant low dose, Deucrictibant high dose, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Terminated | Pharvaris Netherlands B.V. | 34 | 2022-04-19 | 2026-08-17 |
| A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331 - Hereditary Angioedema, HAE | Phase 1 / Phase 2 | Active not recruiting | BioMarin Pharmaceutical | 44 | 2022-02-15 | 2024-05-16 |
| NTLA-2002 in Adults With Hereditary Angioedema (HAE) Biological NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | Intellia Therapeutics | 37 | 2021-12-10 | 2026-09-25 |
| Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema GNR-038, 50 МЕ/ kg, GNR-038, 100 МЕ/ kg, Berinert®, 20 МЕ/ kg - Hereditary Angioedema | Phase 2 / Phase 3 | Withdrawn | AO GENERIUM | 2021-12-01 | 2022-02-04 | |
| A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II KVD824, Placebo to KVD824 - Angioedema, Hereditary, Types I and II | Phase 2 | Terminated | KalVista Pharmaceuticals, Ltd. | 33 | 2021-11-18 | 2026-05-06 |
| Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury C1 Inhibitor, Human, Placebo - Traumatic Brain Injury, Trauma, Head | Phase 2 | Unknown | Leiden University Medical Center | 106 | 2021-02-25 | 2021-09-13 |
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Deucrictibant, Placebo - Hereditary Angioedema, Hereditary Angioedema Type I | Phase 2 | Completed | Pharvaris Netherlands B.V. | 74 | 2021-02-03 | 2025-12-17 |
| Mepolizumab in Episodic Angioedema With Eosinophilia mepolizumab - Eosinophilia, Angioedema | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 5 | 2021-01-14 | 2024-04-16 |
| Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Conestat alfa - Coronavirus Infections | Phase 2 | Terminated | University Hospital, Basel, Switzerland | 80 | 2020-08-06 | 2021-11-09 |
| An Extension Study of Donidalorsen (IONIS-PKK-LRx) in Participants With Hereditary Angioedema Donidalorsen - Hereditary Angioedema | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 20 | 2020-03-31 | 2026-05-08 |
| A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema Donidalorsen, Placebo - Hereditary Angioedema | Phase 2 | Completed | Ionis Pharmaceuticals, Inc. | 23 | 2020-01-07 | 2023-04-03 |
| A Phase II, Cross-over Clinical Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) in the On-demand Treatment of Angioedema Attacks in Adult Subjects With Hereditary Angioedema Type I or II KVD900, Placebo - Hereditary Angioedema | Phase 2 | Completed | KalVista Pharmaceuticals, Ltd. | 84 | 2019-07-02 | 2025-05-02 |
Showing 20 of 45. Sign in to see all of them.
Angioedemas, Hereditary (35) · Hereditary Angioedema Types I and II (8) · Urticaria (3) · Chronic Urticaria (2) · Genetic Diseases, Inborn (2) · Hypersensitivity (2) · Pruritus (2) · Acquired angioedema (1) · Anaphylaxis (1) · Brain Injuries, Traumatic (1) · Bronchial Spasm (1) · COVID-19 (1) · Coronavirus Infections (1) · Craniocerebral Trauma (1)
Cardiovascular Diseases (45) · Hypersensitivity, Immediate (45) · Skin Diseases (45) · Skin Diseases, Vascular (45) · Skin and Connective Tissue Diseases (45) · Vascular Diseases (45) · Immune System Diseases (44) · Hypersensitivity (43) · Urticaria (42) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (35) · Hereditary Complement Deficiency Diseases (35) · Immunologic Deficiency Syndromes (35) · Primary Immunodeficiency Diseases (35) · Genetic Diseases, Inborn (33)
Complement C1 Inhibitor Protein (9) · SERPING1 protein, human (5) · conestat alfa (5) · Sodium Chloride (3) · berotralstat (3) · IONIS-PKK-LRx (2) · avoralstat (2) · donidalorsen (2) · ecallantide (2) · Cortisone (1) · Epinephrine (1) · Injections, Subcutaneous (1) · Omalizumab (1) · RNA, Small Interfering (1) · dupilumab (1)
Shire (6) · BioCryst Pharmaceuticals (5) · Pharming Technologies B.V. (4) · CSL Behring (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Pharvaris Netherlands B.V. (3) · Astria Therapeutics, Inc. (2) · Ionis Pharmaceuticals, Inc. (2) · KalVista Pharmaceuticals, Ltd. (2) · Prothya Biosolutions (2) · ADARx Pharmaceuticals, Inc. (1) · AO GENERIUM (1) · Bernstein, Jonathan A., M.D. (1) · BioMarin Pharmaceutical (1) · Charite University, Berlin, Germany (1)
United States (29) · Germany (22) · United Kingdom (14) · Italy (12) · Canada (11) · Hungary (11) · Netherlands (11) · Poland (11) · Australia (9) · Czechia (9) · North Macedonia (8) · Spain (8) · Bulgaria (7) · France (7) · Israel (7)
Anurag Relan, MD (2) · M. M. Levi, Prof. Dr. (2) · Bruno Giannetti, MD (1) · Henriette Farkas, MD (1) · Hilary Longhurst, MBBS, PhD (1) · Jonathan A. Bernstein, M.D. (1) · Joseph Moellman, MD (1) · Lauge Farnaes, MD (1) · Marc Riedl, MD (1) · Marc Riedl, MD MS (1) · Marcus Maurer, MD (1)
PMID 36326435, PMID 36408587, PMID 19767078, PMID 20674826, PMID 20920772, PMID 23535096, PMID 23878046, PMID 23987198, PMID 24712435, PMID 25601538, PMID 25629740, PMID 26016741, PMID 26171584, PMID 27931305, PMID 28284978, PMID 28754491, PMID 30044938, PMID 30993784, PMID 33397449, PMID 34161665, PMID 34863258, PMID 35219377, PMID 35294812, PMID 35820771, PMID 36774155, PMID 37951310, PMID 37965347, PMID 38006972, PMID 38009241, PMID 38020288, PMID 38294975, PMID 38710185, PMID 39445704, PMID 40490218, PMID 41794053, PMID 41802598, PMID 41865746, PMID 41865747, PMID 42159953, PMID 42268494, PMID 42318595
2023 (2), 2004 (1), 2017 (1), 2018 (1), 2019 (1)